Key clinical point: Researchers have found they can screen pediatric cancer patients for genetic alterations and match those patients to appropriate targeted therapies.
Major finding: Thus far, 24% of the patients screened have been matched and assigned to a treatment, and 10% have been enrolled on treatment protocols.
Study details: Ongoing Pediatric MATCH trial, which has enrolled 422 patients so far.
Disclosures: The trial is sponsored by the National Cancer Institute. The presenter has patents, royalties, and other intellectual property related to genes discovered through sequencing of several adult cancer types.
Parsons DW et al. ASCO 2019, Abstract 10011.